Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12224346 | 1.00 | HPGD (0.54) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL13674774 | 1.00 | HPGD (0.54) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL13674784 | 0.94 | HPGD (0.47) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL13245892 | 0.94 | HPGD (0.47) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL14301360 | 0.94 | HPGD (0.47) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL13041390 | 0.85 | HPGD (0.49) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL20470740 | 0.85 | — | — | |
| SCHEMBL13412867 | 0.85 | HPGD (0.51) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL11892712 | 0.85 | HPGD (0.51) | HPGDSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL8459065 | 0.84 | HPGD (0.54) | HPGDSMN1; SMN2GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064370-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| EP-3670514-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10329304-B2 | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase | VANDERBILT UNIVERSITY (US) | 2019-06-25 | — | — | US | disclosed |
| US-10301272-B2 | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] | PHENEX PHARMACEUTICALS AG (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | VANDERBILT UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | VANDERBILT UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-7563894-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-07-21 | — | — | US | disclosed |
| US-20090069324-A1 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090012094-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2009-01-08 | — | — | US | disclosed |
| WO-2008157003-A2 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-07-10 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329304-B2 | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase | PDE4A, PDE4B, PDE7A | HPGD 544/4885SMN1; SMN2 4025/4885GAA 923/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HPGD 3679/4885SMN1; SMN2 2550/4885GAA 4612/4885 |
| US-20090012094-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | HPGD 2482/4885SMN1; SMN2 4559/4885GAA 1584/4885 |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | HPGD 2482/4885SMN1; SMN2 4559/4885GAA 1584/4885 |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | HPGD 2482/4885SMN1; SMN2 4559/4885GAA 1584/4885 |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | PDE4A, PDE4B, PDE7A | HPGD 544/4885SMN1; SMN2 4025/4885GAA 923/4885 |
| US-20090069324-A1 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | TMBIM6, BCL2L1, BCL2L11 | HPGD 3488/4885SMN1; SMN2 2209/4885GAA 2051/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HPGD 3780/4885SMN1; SMN2 2671/4885GAA 4599/4885 |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | HPGD 1731/4885SMN1; SMN2 1036/4885GAA 3202/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | HPGD 2482/4885SMN1; SMN2 4559/4885GAA 1584/4885 |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | HPGD 2482/4885SMN1; SMN2 4559/4885GAA 1584/4885 |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | HPGD 2482/4885SMN1; SMN2 4559/4885GAA 1584/4885 |
| US-10301272-B2 | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] | RORA, RORB, RORC | HPGD 3181/4885SMN1; SMN2 1570/4885GAA 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.